JP2019528705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528705A5 JP2019528705A5 JP2019512609A JP2019512609A JP2019528705A5 JP 2019528705 A5 JP2019528705 A5 JP 2019528705A5 JP 2019512609 A JP2019512609 A JP 2019512609A JP 2019512609 A JP2019512609 A JP 2019512609A JP 2019528705 A5 JP2019528705 A5 JP 2019528705A5
- Authority
- JP
- Japan
- Prior art keywords
- snp
- sequencing
- treatment
- cancer
- snps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 72
- 238000012163 sequencing technique Methods 0.000 claims description 55
- 239000003153 chemical reaction reagent Substances 0.000 claims description 46
- 230000000295 complement effect Effects 0.000 claims description 32
- 238000002493 microarray Methods 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 239000012472 biological sample Substances 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 16
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 9
- 238000003752 polymerase chain reaction Methods 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical group C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 claims description 6
- 238000001712 DNA sequencing Methods 0.000 claims description 6
- 238000007397 LAMP assay Methods 0.000 claims description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 229950002189 enzastaurin Drugs 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 238000007834 ligase chain reaction Methods 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 238000007480 sanger sequencing Methods 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 238000005251 capillar electrophoresis Methods 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003596 drug target Substances 0.000 claims description 3
- 238000000840 electrochemical analysis Methods 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000012165 high-throughput sequencing Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 235000019689 luncheon sausage Nutrition 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 239000011807 nanoball Substances 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 238000012175 pyrosequencing Methods 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 239000004065 semiconductor Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims 2
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 claims 2
- 102100024923 Protein kinase C beta type Human genes 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 description 10
- 229940043355 kinase inhibitor Drugs 0.000 description 10
- 239000003909 protein kinase inhibitor Substances 0.000 description 10
- 108090000315 Protein Kinase C Proteins 0.000 description 6
- 102000003923 Protein Kinase C Human genes 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 101150116648 rpsP gene Proteins 0.000 description 5
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 102000032170 cAMP response element binding proteins Human genes 0.000 description 2
- 108091010592 cAMP response element binding proteins Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022148064A JP2022173308A (ja) | 2016-09-01 | 2022-09-16 | エンザスタウリンの活性を予測するための方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US62/382,734 | 2016-09-01 | ||
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| US62/414,601 | 2016-10-28 | ||
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142358A Division JP2020188816A (ja) | 2016-09-01 | 2020-08-26 | エンザスタウリンの活性を予測するための方法および組成物 |
| JP2022148064A Division JP2022173308A (ja) | 2016-09-01 | 2022-09-16 | エンザスタウリンの活性を予測するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528705A JP2019528705A (ja) | 2019-10-17 |
| JP2019528705A5 true JP2019528705A5 (enExample) | 2020-10-08 |
| JP7197915B2 JP7197915B2 (ja) | 2022-12-28 |
Family
ID=59923555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512609A Active JP7197915B2 (ja) | 2016-09-01 | 2017-08-31 | エンザスタウリンの活性を予測するための方法および組成物 |
| JP2020142358A Pending JP2020188816A (ja) | 2016-09-01 | 2020-08-26 | エンザスタウリンの活性を予測するための方法および組成物 |
| JP2022148064A Withdrawn JP2022173308A (ja) | 2016-09-01 | 2022-09-16 | エンザスタウリンの活性を予測するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142358A Pending JP2020188816A (ja) | 2016-09-01 | 2020-08-26 | エンザスタウリンの活性を予測するための方法および組成物 |
| JP2022148064A Withdrawn JP2022173308A (ja) | 2016-09-01 | 2022-09-16 | エンザスタウリンの活性を予測するための方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (enExample) |
| EP (1) | EP3507384B1 (enExample) |
| JP (3) | JP7197915B2 (enExample) |
| KR (1) | KR20190046935A (enExample) |
| CN (1) | CN109952383B (enExample) |
| AU (1) | AU2017318669B2 (enExample) |
| BR (1) | BR112019003951A2 (enExample) |
| CA (1) | CA3035386A1 (enExample) |
| JO (1) | JOP20190025A1 (enExample) |
| MX (1) | MX2019002377A (enExample) |
| PH (1) | PH12019500422A1 (enExample) |
| RU (1) | RU2019109011A (enExample) |
| SG (2) | SG10201912134TA (enExample) |
| TW (2) | TW202313973A (enExample) |
| WO (1) | WO2018045240A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| EP4376022A4 (en) * | 2021-07-23 | 2025-07-16 | Univ Kaohsiung Medical | CLINICAL THERAPEUTIC DRUG PREDICTION AND RECOMMENDATION SYSTEM AND METHOD FOR EVALUATING THE EFFICACY OF A SECOND-GENERATION HORMONAL DRUG IN THE TREATMENT OF PROSTATE CANCER |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| CN118339312A (zh) * | 2021-11-23 | 2024-07-12 | 索元生物医药(美国)有限公司 | 用于评估多核苷酸递送和癌疗法之功效的组合物和方法 |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| WO2002014500A2 (en) | 2000-08-16 | 2002-02-21 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2012106267A1 (en) | 2011-01-31 | 2012-08-09 | Wen Luo | Method for discovering pharmacogenomic biomarkers |
| CN103649386B (zh) * | 2011-06-08 | 2015-12-23 | 索元生物医药（杭州）有限公司 | 预测类视黄醇x受体调节剂活性的方法和组合物 |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Ceased
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh not_active IP Right Cessation
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528705A5 (enExample) | ||
| AU2017200433B2 (en) | Multivariate diagnostic assays and methods for using same | |
| Reeser et al. | Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors | |
| Wang et al. | Single cell sequencing: a distinct new field | |
| CN105358709B (zh) | 用于检测基因组拷贝数变化的系统和方法 | |
| RU2019109011A (ru) | Композиции и способы с использованием фармакогеномного маркера | |
| EP3180432A1 (en) | Library generation for next-generation sequencing | |
| JP2007525998A (ja) | 脆弱ｘ症候群などのｓｔｒｐの検出 | |
| JP2016510992A (ja) | ゲノムＤＮＡおよびｃＤＡＮの両方を含む全核酸の濃縮および次世代シークエンシング | |
| JP7761619B2 (ja) | 核酸の正確な並行検出及び定量のための方法 | |
| JP2022145606A (ja) | 核酸の正確な並行定量のための高感度な方法 | |
| EP3105324B1 (en) | Ngs systems control and methods involving the same | |
| US20160208240A1 (en) | Ngs workflow | |
| CN105431738A (zh) | 胃癌的预后预测模型的建立方法 | |
| CN105189780A (zh) | 核酸制备和分析的组合物和方法 | |
| WO2016172126A2 (en) | Experimentally validated sets of gene specific primers for use in multiplex applications | |
| US20170137807A1 (en) | Improved ngs workflow | |
| Kirchhoff et al. | Germline genetics in immuno-oncology: from genome-wide to targeted biomarker strategies | |
| JP7762690B2 (ja) | 変異核酸の正確な並行定量するための高感度方法 | |
| RU2749465C1 (ru) | Способ определения генетических маркеров для оценки полигенного риска развития рака молочной железы (гормон-негативного и гормон-позитивного подтипов) | |
| KR102353064B1 (ko) | Her2 복제수 변이 검출용 조성물 및 이를 포함하는 키트 | |
| KR101075392B1 (ko) | Ｆｇａ 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 이를 이용한 검출 방법 | |
| Camps et al. | New Technologies in Translational Medicine | |
| Work | Targeted RNA Sequencing: Unraveling the Detection Principles, Workflow and Diverse Applications | |
| HK1260078A1 (en) | Deep sequencing profiling of tumors |